By this method, we found intact FH expression in the patient's lesion (Figure 2(c)) suggesting that the tumor most likely arose in a sporadic fashion and offering no overt evidence of FH deficiency or the HLRCC syndrome in the patient, although it should be remembered that FH immunohistochemistry is only 83% sensitive and 75% specific for HLRCC, and intact FH expression does not entirely exclude the possibility of HLRCC [5]. The gene discussed is FH; the disease is hereditary leiomyomatosis and renal cell cancer.